2 June, 2008 -- ProStrakan Group plc (LSE: PSK) announces today that, as a result of continuing discussions with the US Food & Drug Administration (FDA), it believes that there are now no outstanding technical questions from the FDA's review of Sancuso® other than those which will be dealt with in labeling negotiations. Sancuso is ProStrakan's novel, patent-protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).
The whole story can be read here.
No comments:
Post a Comment